Tirzepatide
Tirzepatide (Mounjaro/Zepbound)
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. Demonstrates significant weight loss and metabolic improvements in large clinical trials.
Key Research
Peer-Reviewed Evidence • 3 Citations
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
Frias JP et al.•N Engl J Med•2021•PMID: 34170647
Key Finding: Tirzepatide demonstrated superior HbA1c reduction and weight loss compared to semaglutide across all doses in head-to-head trial.
View on PubMedTirzepatide for treatment of adults with overweight or obesity (SURMOUNT-1)
Jastreboff AM et al.•N Engl J Med•2022•PMID: 35658024
Key Finding: Tirzepatide achieved 22.5% weight loss at highest dose — transformative results for obesity pharmacotherapy.
View on PubMedDual GIP/GLP-1 receptor agonism: An emerging approach for treating type 2 diabetes and obesity
Nauck MA, D'Alessio DA•Diabetes Obes Metab•2020•PMID: 32267090
Key Finding: Dual incretin agonism provides additive metabolic benefits through complementary pathways, offering superior efficacy to single-target drugs.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📊 Evidence by Outcome
FDA-approved. SURMOUNT trials showed up to 22.5% weight loss at highest dose.
15 studies • Consistency: High • Effect: Very Large
Superior HbA1c reduction compared to other diabetes medications.
12 studies • Consistency: High • Effect: Large
👥 Community Insights
Mounjaro changed my life. Down 20kg and A1c normalized.
Community member • Dubai• Verified
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Where to Get It (UAE)
Browse all wellness centers →Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.